Lirilumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase I drugs for Muscle Invasive Bladder Cancer (MIBC) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lirilumab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lirilumab (IPH-2102, BMS-986015) is under development for the treatment of hematologic tumors including refractory or relapsed multiple myeloma and muscle invasive bladder cancer. The drug candidate is administered intravenously. It targets killer cell immunoglobulin-like receptor 2DL 1, 2 and 3.
It was also under development for castrate resistant prostate cancer, colorectal cancer, metastatic melanoma, advanced solid tumors including non-small cell lung cancer, gastrointestinal tract cancer, head and neck cancer, squamous cell carcinoma, hepatocellular carcinoma, myelodysplastic syndrome, Hodgkin lymphoma, non-Hodgkin lymphoma and acute myeloid leukemia (AML).
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Lirilumab’s drug-specific PTSR and LoA scores, buy the report here.